Answers are grounded in this paper and cite their sources.
This research investigates how inflammation influences drug resistance in colorectal cancer, suggesting new therapeutic targets.
The intricate relationship between inflammation and cancer progression has been well-documented, with chronic inflammation playing a pivotal role in tumor development and drug resistance. This project investigates how cancer-intrinsic inflammation influences drug response, aiming to identify key regulators that could serve as therapeutic targets to overcome drug resistance in colorectal cancer (CRC). We hypothesize that distinct inflammation types within cancer cells modulate their response to chemotherapy, potentially driving resistance. Our study is structured around two specific aims: First, we investigate the inflammation-type-dependent drug response using single-cell barcoded colon cancer cells. Our preliminary studies demonstrated that CRC cells in an inflamed microenvironment, particularly those with STING pathway activation, exhibit distinct responses to 5-FU treatment compared to non-inflamed cells. This finding underscores the need to consider inflammation as a critical factor in cancer treatment strategies. By characterizing the response of inflamed and non-inflamed cells to various drug treatments at single-cell resolution, we aim to identify the specific inflammation-driven mechanisms that contribute to drug resistance. Second, we focus on the characterization and validation of key regulators identified in inflamed CRC cells. We will validate candidate genes through functional assays, including gene knockdown experiments, to uncover the molecular pathways through which inflammation modulates drug response. By linking the distinct inflammatory states within cancer cells to drug resistance, we aim to identify novel biomarkers and therapeutic targets that could enhance the effectiveness of existing treatments. Our research has the potential to significantly impact the treatment of CRC by providing a deeper understanding of how inflammation drives drug resistance, ultimately guiding the development of more effective, personalized therapies for patients with inflamed tumors. This approach addresses the urgent need for targeted strategies to overcome the challenges posed by inflammation-associated drug resistance in cancer therapy. Citation Format: Kerem Fidan, Semih Can Akincilar, Tim Stuart, Vinay Tergaonkar. Deciphering Inflammation-Driven Drug Resistance Mechanisms in Colorectal Cancer through Single-Cell Barcoding [abstract]. In: Proceedings of Frontiers in Cancer Science 2024; 2024 Nov 13-15; Singapore. Philadelphia (PA): AACR; Cancer Res 2025;85(15_Suppl):Abstract nr P71.
No takes yet. Share an insight, caveat, or question.
Fidan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: